Endoscopic Treatment of Dieulafoy Lesions and Risk Factors for Rebleeding by Lim, Won et al.
Endoscopic Treatment of Dieulafoy Lesions and Risk Factors
for Rebleeding
Won Lim, Tae Oh Kim, Su Bum Park, Ha Rin Rhee, Jin Hyun Park, Jung Ho Bae, Hong Ryeul Jung, Mi Ra Kim,
NaRiA Lee, Sun Mi Lee, Gwang Ha Kim, Jeong Heo, and Geun Am Song
Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea
DOI: 10.3904/kjim.2009.24.4.318
ORIGINAL ARTICLE
Background/Aims: Dieulafoy lesions are an important cause of upper gastrointestinal bleeding. The purpose of
this study was to assess the efficacy of endoscopic treatment for these lesions and to identify the possible
predictive factors for rebleeding associated with clinical and endoscopic characteristics.
Methods: Records from 44 patients admitted with Dieulafoy bleeding between January 2006 and December
2007 were reviewed. We retrospectively analyzed the clinical and endoscopic findings and then correlated the
rebleeding risk factors with Dieulafoy lesions.
Results: Primary hemostasis was achieved by endoscopic treatment in 39 patients (88.6%). There were no
significant differences between the rebleeding and non-rebleeding groups with respect to age, gender, initial
hemoglobin levels, presence of shock, concurrent disease, location of bleeding, or initial hemostatic treatment
methods. However, the use of non-steroidal anti-inflammatory drugs or anticoagulants (p=0.02) and active stages
in the Forrest classification (p<0.01) were risk factors for rebleeding after endoscopic therapy.
Conclusions: Endoscopic therapy is effective and safe for treating Dieulafoy lesions, and it has both short- and
long-term benefits. Early identification of risk factors such as the use of non-steroidal anti-inflammatory drugs or
anticoagulants and the Forrest classification of bleeding predict the outcome of Dieulafoy lesions. (Korean J Intern
Med 2009;24:318-322)
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INTRODUCTION
Upper gastrointestinal (GI) bleeding is a common
medical emergency in clinical practice, and Dieulafoy
lesions are an important cause of potentially life-
threatening GI bleeding. Typically, these lesions consist of
large-caliber submucosal arteries in close contact with the
mucosa over a variable distance, and massive bleeding can
occur with erosion of the mucosa and arterial wall [1].
These lesions are responsible for 0.5 to 14% of acute upper
GI bleeding [2]. Most lesions are located in the proximal
stomach, but they can also be found in other GI tract
locations [3]. The therapy for this condition has evolved 
from surgery to endoscopy. 
In addition to the different endoscopic techniques used
for GI bleeding, such as injection with or without thermal
therapy, mechanical methods such as the use of hemoclips
and rubber band ligation have recently been used.
The aims of the study were to assess the efficacy of
endoscopic treatment for Dieulafoy lesions and to identify
possible predictive factors for rebleeding in patients with
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METHODS
Patients
Between January 2006 and December 2007, 312
patients with nonvariceal upper GI bleeding were
admitted to Pusan National University Hospital. A total of
44 patients with a Dieulafoy lesion in the upper GI tract
were examined. After basic life support was provided, all
patients underwent emergent endoscopy. All procedures
were performed by two expert endoscopists within 12
hours of patient admission. Informed consent was obtained
from every patient or from family members. All patients
received only topical analgesics and an intravenous proton
pump inhibitor. No systemic sedative agent was given to
any patient. Follow-up endoscopy was performed within
24 hours of the initial procedure and at 7 days. Patient
data were collected during hospitalization and included
demographic information, medical history, initial hemo-
dynamic status, laboratory values, endoscopic findings,
endoscopic therapy, and outcome (i.e., complications,
death, rebleeding, and the need for surgery). Information
on rebleeding and mortality following discharge was
obtained during follow-up outpatient visits. Because this
study was a retrospective review, institutional review
board approval was not necessary.
Definitions
The endoscopic diagnosis of a Dieulafoy lesion was
based on the following established criteria [3]: 1) active
arterial spurting or micropulsatile streaming from minute
(<3 mm) mucosal defects, 2) visualization of a protruding
vessel with or without active bleeding within a minute
mucosal defect with normal surrounding mucosa, or 3) a
densely adherent clot with a narrow attachment point to a
minute mucosal defect or normal-appearing mucosa.
Initial hemostatic failure was defined as sustained active
bleeding despite initial endoscopic management or any
evidence of active bleeding, such as hematemesis, hema-
tochezia, or hemodynamic instability (systolic blood
pressure <100 mm Hg, pulse rate >100 beats/minutes, or
an orthostatic change in systolic blood pressure >20 mm
Hg or a pulse rate >20 beats/minutes) within 12 hours of
the initial hemostasis. Rebleeding was suspected in
patients with additional episodes of hematemesis or in
those with melena, hemodynamic instability, or a decrease
in hemoglobin concentration of at least 2 g/dL in 24 hours
and diagnosed when the endoscopy showed bleeding from
a previously treated lesion. 
Statistical analysis
The Mann-Whitney test was used to compare the mean
values of continuous variables, and Fisher’s exact test was
used to compare non-ratio variables. The analysis was
conducted with SPSS version 13.0 (SPSS Inc., Chicago,
IL, USA). A p value of less than 0.05 was accepted as
statistically significant.
RESULTS
During the study period, 44 Dieulafoy lesions were
identified among 312 endoscopies performed for non-
variceal upper GI bleeding (Table 1). The locations of the
bleeding lesions were as follows: proximal stomach, 28;
mid-stomach, 6; and distal stomach, 10. In all, 24 patients
(54.5%) were bleeding at the time of diagnosis: 4 had
spurting, and 20 had an oozing hemorrhage. The remaining
20 patients had a nonbleeding visible vessel or an
adherent clot. The following hemostatic methods were
used as therapeutic procedures: band ligation (4 patients),
hypertonic saline-epinephrine injection (2 patients),
hemoclipping (15 patients), and hypertonic saline-
epinephrine injection with hemoclipping (23 patients). In
the treatment group, primary hemostasis was achieved in
39 patients (88.6%). Five patients with initial failure of
hemostasis required emergent transarterial embolization
because of continuous bleeding at sites difficult to
approach. In three, permanent hemostasis was achieved
by transarterial embolization. In addition, two patients
Table 1. Endoscopic findings and hemostatic
methods
Parameters No. (%)
(n=44)
Location
Proximal stomach 28 (63.6)
Mid-stomach 6 (13.7)
Distal stomach 10 (22.7)
Forrest classification 
Ia/Ib/IIa/IIb/IIc/III 4 (9.1)/20 (45.5)/18 (40.9)/2 (4.5)/0/0
Hemostatic methods
Band ligation 4 (9.1)
HSE injection 2 (4.5)
Hemoclipping 15 (34.1)
HSE injection+Hemoclipping 23 (52.3)
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Table 2. Clinical characteristics of the rebleeding and non-rebleeding groups
Parameters Rebleeding group Non-rebleeding group p value
(n=7) (n=32)
Age, yr 66.6±12.8 59.7±12.9 NS 
Sex, male/female 6 (85.7)/1 (14.3) 22 (68.8)/10 (31.2) NS
NSAIDs or anticoagulant intake 5 (71.4) 7 (21.8) 0.02
Concomitant disease 3 (42.9) 10 (31.3) NS
Initial hemoglobin <10 g/dL 4 (57.1) 12 (37.5) NS
Systolic blood pressure <100 mmHg 2 (28.5) 14 (43.7) NS
Location NS
Proximal stomach 5 (71.4) 19 (59.4)
Mid-stomach 1 (14.3) 5 (15.6)
Distal stomach 1 (14.3) 8 (25.0)
Forrest type <0.01
Ia/Ib/IIa/IIb/IIc/III 5 (71.4)/2 (28.6)/0/0/0 2 (6.3)/17 (53.1)/12 (37.5)/1 (3.1)/0
Hemostatic method NS
Band ligation 1 (14.3) 3 (9.4)
HSE injection 1 (14.3) 1 (3.1)
Hemoclipping 3 (42.8) 9 (28.1)
HSE injection+Hemoclipping 1 (14.3) 19 (59.4)
Angiography 1  (14.3) 0  (0)
Values are number (%).
NSAIDs, non-steroidal anti-inflammatory drugs; HSE, hypertonic saline epinephrine; NS, not significant.
Figure 1. Summary of the management pathways and treatment outcomes.
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received surgery. Seven patients (17.9%) had recurrent
bleeding 1-3 days after the initial endoscopic procedure,
and another endoscopic hemoclipping or angiography
with embolization resulted in permanent hemostasis.
There were no significant differences between the
rebleeding and non-rebleeding groups with respect to age,
gender, initial hemoglobin levels, presence of shock,
concurrent disease, bleeding location, or initial hemostatic
methods. However, there was a statistically significant
difference in the use of non-steroidal anti-inflammatory
drugs (NSAIDs) or anticoagulants and in the Forrest
classification of bleeding (p=0.02 and p<0.01, Table 2). A
summary of the management and treatment outcomes is
provided in Fig. 1. Among the 44 patients discharged from
the hospital, 6 were lost to follow-up and 38 were available
for assessment. The mean follow-up was 15 months
(range, 5 to 29). During the outpatient follow-up, there was
no recurrence of bleeding, and there were no procedure-
related complications. 
DISCUSSION
Although Dieulafoy lesions are an uncommon cause
of GI bleeding [4], the results of our study show them to
be a relatively frequent cause, accounting for 14.1% of
nonvariceal upper GI bleeding. As in previous reports,
many patients had significant comorbidities, and the
ingestion of aspirin, NSAIDs, or warfarin was common. The
clinical features of the patients with Dieulafoy lesions were
similar to those of patients reported previously [2,5-8]. 
Endoscopic therapy, which has emerged as the mainstay
for managing Dieulafoy lesions, is safe and highly successful
in terms of achieving initial hemostasis [2,9]. There are
many reports of successful hemostasis using a variety of
endoscopic modalities, including injection of sclerosants
[2,10,11], thermal coagulation [5,10], and mechanical
methods such as band ligation [12] or hemoclip application
[13]. The success rate of various forms of endoscopic
therapy range from 75 to 98% [10,14-16]. In the present
study, primary hemostasis was achieved in 39 patients
(88.6%). If endoscopic therapy fails, management with
other options such as transarterial embolization or
surgery is indicated. Five patients with initial failure of
hemostasis required emergent transarterial embolization
and surgery, and all had permanent hemo-stasis. Seven
patients (17.9%) had rebleeding 1-3 days after the initial
endoscopic procedure, and endoscopic retreatment
and transarterial embolization resulted in permanent
hemostasis. 
There was a significant difference in the intake of NSAIDs
and anticoagulants as well as in the type of bleeding
between the rebleeding group and the non-rebleeding
group.
Long-term results for patients treated by endoscopic
methods are excellent [12,17,18], and mortality is generally
low with prompt diagnosis and treatment. In our study,
the mean follow-up was 15 months. During the outpatient
follow-up, there was no recurrence of bleeding, and there
were no procedure-related complications.
This study has several limitations. The first limitation is
the small sample size and the retrospective design.
Medical records that are not designed for research
purposes may not include all of the variables of interest or
may contain inaccurate descriptions. In addition, there
was limited power to show statistical differences because
of the small sample size. The second limitation is that this
series of patients was enrolled from a single institution
and reflected a number of factors associated with this
institution; therefore, the post-discharge outcome data
may be incomplete. However, we believe that most patients
discharged from our hospital would return to the same
institution if upper GI bleeding recurred. The third
limitation is the impact of treatment. Although we limited
the drug options for acute bleeding, the drugs chosen
reflect the preferences of the clinical physicians; however,
we believe these drug options did not influence the results
of the study. 
Despite these limitations, this study remains important
for demonstrating the efficacy of endoscopic treatment for
Dieulafoy lesions and the factors associated with rebleeding
in the context of these patients and the diagnostic and
treatment algorithm. 
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